ArticleThe Journal of clinical investigation2022

Targeting hepatic kisspeptin receptor ameliorates nonalcoholic fatty liver disease in a mouse model.

Stephania Guzman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.